Formycon publishes scientific article on FYB206 biosimilar development
Formycon AG announced the publication of a scientific article in the journal BioDrugs detailing the scientific and regulatory principles of an innovative, evidence-based developmental approach for biosimilars, using its pembrolizumab biosimilar candidate FYB206 as an example. The article illustrates how a pharmacokinet